Cytovia, Cellectis partner on gene-edited NK cells Cytovia Therapeutics and Cellectis have entered into a strategic research and development collaboration to develop gene-edited natural killer (NK) and chimeric antigen receptor NK cells derived from induced pluripotent stem cells.Read More
Dyno publishes data on optimized AAV capsids for gene therapy Dyno Therapeutics recently highlighted an article in Nature Biotechnology that demonstrates the use of its artificial intelligence platform to generate diverse adeno-associated virus (AAV) capsids with functional variants capable of evading the immune system.Read More
Cellaria, BioLamina partner on new cell culture models Cellaria and BioLamina have announced that they plan to collaborate on developing new cell culture models for cancer research, tissue modeling, drug screening, and research in basic and regenerative medicine.Read More
Notch nabs $85M in funding for stem cell-based cell therapies Notch Therapeutics has closed $85 million in series A financing to continue the development of its portfolio of induced pluripotent stem cell-derived cell therapies for cancer, as well as its proprietary engineered Thymic Niche platform.Read More
Researchers use modified CRISPR tool to manipulate the epigenome Bioengineers have developed a new way to engineer the human epigenome (chemical changes in the DNA) using a modified CRISPR-Cas9 system to target and activate proteins in the chromosome. This research, published in Nature Communications on February 9, expands on synthetic genome tools.Read More